Physician profile
Travis Boss
NPI 1538904297
$1,890.92
in general payments reported to CMS, 2019-2025
18 companies · $1,585 in 2025
The $1,585 reported for 2025 was more than what 93% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $306 · 2025: $1,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,890.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $495.62 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $299.92 | 2025 | |
| Lilly USA, LLC | $228.87 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $215.55 | 2024-2025 | Airsupra, Breztri |
| Corcept Therapeutics | $147.04 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $96.55 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $78.80 | 2024-2025 | |
| Amgen INC. | $64.07 | 2024-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $45.18 | 2025 | Veozah |
| Lundbeck LLC | $41.99 | 2024-2025 | Vyepti |
| Sumitomo Pharma America, INC. | $39.10 | 2025 | Gemtesa, Myfembree |
| Biogen, INC. | $23.62 | 2024 | Skyclarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.55 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $22.57 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.02 | 2025 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.81 | 2025 | Xifaxan |
| Gilead Sciences, INC. | $15.36 | 2024 | |
| Nevro Corp. | $13.30 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Boss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.